Neuromyelitis Optica (Devic's Syndrome) Market is segmented By Product Type (Eculizumab, Methylprednisolone, Azathioprine, Mycophenolate Mofetil, Rituximab), By Application (Hospitals, Clinics, Homecare and Telemedicine), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Report Overview
The Neuromyelitis Optica (Devic's Syndrome) Market is estimated to reach at a CAGR of 4.8% during the forecast period 2024-2031.
Neuromyelitis optica spectrum disorder (NMOSD) ,known as Devic disease, is a chronic disorder of the brain and spinal cord which is dominated by inflammation of the optic nerve (optic neuritis) and inflammation of the spinal cord (myelitis).
Market Summary
|
Metrics |
Details |
|
Market CAGR |
4.8% |
|
Segments Covered |
By Product Type, By Application, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
To Get a Free Sample Click here
Market Dynamics
An increase in neuromyelitis optica (Devic's syndrome ) incidence will drive the market. Morever increase in research and development by key players will see a rise in its market.
An increase in neuromyelitis optica (Devic's syndrome ) incidence will drive the market
Neuromyelitis optica or NMO is also called devic's disease , is an immunological disorder. It is often characterized by immune attacks on the optic nerves (which transmit what you see to your brain) and the spinal cord. The FDA recently approved two drugs to treat it. Eculizumab (Soliris), inebilizumab-cdon (Uplizna), and satralizumab-mwge (Enspryng) they work by targeting the defective antibodies that attack the healthy cells in your body, triggering NMO. A doctor may prescribe other drugs to suppress the immune system.
NMOSD occurs in individuals of all races. Its prevalence is approximately 1-10 per 100,000 individuals. Though somewhat higher rates have been reported in countries with a higher proportion of individuals of African ancestry, it seems to be similar worldwide.
An increase in research and development will increase the market in the forecast period
In recent years, scientists and clinical neurologists have gained enormous interest in the condition, fuelled by detecting a specific serum immunoglobulin (Ig)G reactivity (NMO-IgG) in up to 80% of patients with NMO. These autoantibodies were later shown to target aquaporin-4 (AQP4), the most abundant water channel in the central nervous system (CNS).
The U.S. FDA has approved Soliris (eculizumab) injection in the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive for intravenous use. NMOSD is an autoimmune disease of the CNS that affects the optic nerves and spinal cord. Soliris provided the first FDA-approved treatment for neuromyelitis optica spectrum disorder, a debilitating disease.
Genentech Inc. for Enspryng (satralizumab-mwge) is approved as a treatment for the rare autoimmune condition neuromyelitis optica spectrum disorder (NMOSD) by the U.S. Drug and Food Administration.
Unavailability of disease specific treatment will hamper the market
Neuromyelitis Optica (Devic's Syndrome) is a relatively rare disease, there are have been no large-scale studies of treatment for this disease. Treatment for an acute attack of Devic's begins with intravenous steroids and is then followed by oral steroids. Incase the steroids are not effective, a treatment known as plasmapheresis is generally used. This therapy cleans the antibodies from the blood by circulating them through a machine, similar to how dialysis works. This disease does not appear to respond to standard medications for multiple sclerosis. There is no cure, but their medicines and treatments may inhibit future disease flares.Patients with neuromyelitis optica (NMO) patients have a 91% to 98% five-year survival rate. Current research indicates that neuromyelitis optica (NMO) patients have a 91% to 98% five-year survival rate.
COVID-19 Impact Analysis on Market
COVID-19 has impacted the healthcare sector and also has a notable impact on the Neuromyelitis Optica (Devic's Syndrome) Market The admissions due to neuromyelitis optica (Devic's Syndrome) have gone down with increasing demand for COVID-19 treatment in hospitals, and even pharmaceutical companies' interest was more in the development of vaccines for COVID-19. Hence the market was affected by COVID-19.
Market Segmentation Analysis
Eculizumab will dominate this segment of the market
Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease of the CNS distinct from multiple sclerosis and typically presents with a relapsing course of optic neuritis, myelitis and midline brain inflammatory lesions. In at least two-thirds of cases, antibodies against the water channel AQP4 can be found, leading to an antibody-mediated activation of the complement system with consecutive damage to neuronal structures. Eculizumab, a humanized monoclonal antibody against the terminal complement component 5, was shown to significantly reduce the risk of NMOSD relapse in Phase III placebo-controlled trial. Based on this, eculizumab (Soliris®) was the first drug to be formally approved to treat anti-AQP4antibody-positive NMOSD in 2019.
The U.S. FDA has approved Soliris (eculizumab) injection for intravenous use in the treatment of neuromyelitis optica spectrum disorder (NMOSD) in patients with anti-aquaporin-4 (AQP4) antibody positive.
The hospital segment will dominate the market
Treatment for NMO generally consists of two parts: addressing current attack and preventing the future attacks. During the initial attack, healthcare team will try to get the condition and its symptoms under control. Treatment at this stage is often intravenous corticosteroids and plasma exchange (PLEX).
More than 90% of patients with NMO experience more than one attack, with the attacks being usually severe. Doctors typically recommend ongoing treatment to help prevent future attacks and disease progression. This usually involves immunotherapy, which is a type of treatment that modulates the immune system. The patient should be assisted by doctors during this treatment, and hospitals provide a better facility for the treatment.
Market Geographical Share
North America will dominate neuromyelitis optica (Devic's Syndrome) market in the forecast period
Increased incidence of neuromyelitis optica (Devic's Syndrome) and major key players in this region will drive the market.
There are approximately 1,000 to 3,000 Canadians living with NMOSD, with the disease being most commonly diagnosed among non-Caucasian women in their 20s to 40s. People with NMOSD experience unpredictable, severe relapses causing cumulative, permanent neurological damage and disability.
The U.S. Drug and Food Administration has approved Genentech Inc. for Enspryng (satralizumab-mwge). AR 50% of patients with NMOSD have permanent visual impairment and paralysis. In the U.S, it is thought to affect approximately 4,000-8,000 Americans.
Market Companies and Competitive Landscape
Some prominent key players in this market are Alexion Pharmaceuticals, Inc., Hoffmann-La Roche Ltd, Viela Bio, Genentech, Inc., AstraZeneca, Shanghai Pharmaceutical Group Co., Ltd., China Resources Pharmaceutical GroupCo., Ltd. and Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd. SAGENT PHARMACEUTICALS, INC. and ZYDUS PHARMACEUTICALS, INC.
Key Companies to Watch
Alexion Pharmaceuticals, Inc
Overview: Alexion Pharmaceuticals Inc best known for its development of Soliris, is an American pharmaceutical company which developed a drug used to treat the rare disorders atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria. It is also involved in immune system research related to autoimmune diseases.
Product Portfolio: The company's mission is to transform the lives of people living with rare diseases,devastating conditions through the development , delivery of innovative medicine, supportive technologies, and healthcare services.
Key Development: On Jun. 27, 2019, Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) announced that the U.S. FDA has approved SOLIRIS® (eculizumab) for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients with anti-aquaporin-4 (AQP4) antibody positive.1 Approximately three-quarters (73%) of all patients with NMOSD test positive for anti-AQP4 auto-antibodies.2 The FDA approved SOLIRIS following an expedited six-month priority review.
The Neuromyelitis Optica (Devic's Syndrome) Market report would provide an access to an approx. 52 market data table, 43 figures and 200 pages.
